A Study to Assess the Effectiveness of Aflibercept in Routine Clinical Practice in Patients With Diabetic Macular Oedema
Status:
Completed
Trial end date:
2020-11-23
Target enrollment:
Participant gender:
Summary
Intravitreal aflibercept has been approved for the treatment of visual impairments due to
diabetic macular oedema (DMO) in Europe and the US in August 2014 and July 2014 respectively.
The main objectives of this observational cohort field study are to evaluate effectiveness of
intravitreal aflibercept and to describe follow-up as well as treatment patterns in anti
vascular endothelial growth factor (anti-VEGF) treatment naïve patients with DMO in routine
clinical practice in the United Kingdom.